STLNW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• Three Months Ended June 30,ChangeSix Months Ended June 30,Change

• The increase in patient services revenue for the three and six months ended June 30, 2026 compared to the same periods in the prior year was primarily due to a 48% and 51% increase in capitated revenue, respectively, partially offset by a 17% and 13% decrease, respectively in fee-for-service revenue…

• The increase in specialty pharmacy revenue for three and six months ended June 30, 2026 as compared to the same periods in the prior year was primarily driven by continued strength in prescription fill volumes as the Company continues to bring new capitated lives onto the platform, along with the on…

• Three Months Ended June 30,ChangeSix Months Ended June 30,Change

• The increase in patient services cost for the three months ended June 30, 2026 as compared to the same quarter prior year was primarily due to a 17.3% increase in clinical payroll costs as the Company adjusts physician compensation to better match performance and volume, primarily offset by 11.7% de…

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• The increase in patient services revenue for the three months ended March 31, 2026 compared to the same period in the prior year was primarily due to a 54% increase in capitated revenue, partially offset by a 10% decrease in fee-for-service revenue. This was driven by momentum in new markets in addi…

• The increase in specialty pharmacy revenue for three months ended March 31, 2026 as compared to the same quarter prior year was primarily due to a 102.8% increase in the number of fills due to the continued growth in the attachment of prescriptions to our patient visits, offset by a 12.4% decrease i…

• our capitated and fee-for-service lives, and improved performance of our retail and MID pharmacies through higher prescription volumes and greater pharmacy attachment within our network.

• The increase in patient services cost for the three months ended March 31, 2026 as compared to the same quarter prior year was primarily due to a 10% increase in clinical payroll costs as the Company adjusts physician compensation to better match performance and volume.

• The increase in specialty pharmacy cost for the three months ended March 31, 2026 was primarily due to a 102.8% increase in the number of prescriptions filled offset by a 12.5% decrease in the average cost of the prescriptions filled, as compared to the same quarter prior year.

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• None of the Company’s directors or officers adopted, modified or terminated a Rule 10b-5 trading arrangement or a non-Rule 10b-5 trading arrangement as such terms are defined under Item 408(a) of Regulation S-K, during the three months ended June 30, 2026.

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• During the three months ended December 31, 2025, Mohit Kaushal, a director of the Company, adopted a Rule 10b5-1 trading plan as of December 16, 2025 providing for the sale of up to an aggregate amount of 105,719 shares of common stock during the period until October 1, 2026. This trading plan was e…

• None of the Company’s directors or officers adopted, modified or terminated a Rule 10b-5 trading arrangement or a non-Rule 10b-5 trading arrangement during the three months ended March 31, 2026, as such terms are defined under Item 408(a) of Regulation S-K.